Merus (NASDAQ:MRUS) Shares Sold by US Bancorp DE

US Bancorp DE cut its position in Merus (NASDAQ:MRUS) by 66.3% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 692 shares of the biotechnology company’s stock after selling 1,362 shares during the period. US Bancorp DE’s holdings in Merus were worth $29,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Gordian Capital Singapore Pte Ltd grew its stake in Merus by 10.4% during the 3rd quarter. Gordian Capital Singapore Pte Ltd now owns 5,000 shares of the biotechnology company’s stock worth $250,000 after purchasing an additional 470 shares in the last quarter. Harbor Capital Advisors Inc. grew its stake in Merus by 2.2% during the 4th quarter. Harbor Capital Advisors Inc. now owns 43,208 shares of the biotechnology company’s stock worth $1,817,000 after purchasing an additional 921 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Merus by 10.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,517 shares of the biotechnology company’s stock worth $610,000 after purchasing an additional 1,398 shares in the last quarter. Avior Wealth Management LLC purchased a new stake in Merus during the 4th quarter worth about $76,000. Finally, MML Investors Services LLC purchased a new stake in Merus during the 3rd quarter worth about $206,000. 96.14% of the stock is owned by institutional investors and hedge funds.

Merus Stock Up 1.3 %

MRUS opened at $47.00 on Thursday. The business has a 50 day moving average price of $43.15 and a two-hundred day moving average price of $46.26. The company has a market cap of $3.25 billion, a PE ratio of -11.90 and a beta of 1.15. Merus has a 52 week low of $37.77 and a 52 week high of $61.61.

Merus (NASDAQ:MRUS) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.48. The firm had revenue of $9.14 million during the quarter, compared to the consensus estimate of $10.57 million. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. As a group, sell-side analysts expect that Merus will post -3.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on MRUS. Piper Sandler began coverage on Merus in a report on Thursday, February 13th. They set an “overweight” rating and a $84.00 price target for the company. William Blair reaffirmed an “outperform” rating on shares of Merus in a report on Friday, February 28th. Bank of America decreased their price target on Merus from $73.00 to $70.00 and set a “buy” rating for the company in a report on Monday, March 10th. Citigroup lifted their price target on Merus from $89.00 to $97.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Finally, Guggenheim reaffirmed a “buy” rating and set a $109.00 price target on shares of Merus in a report on Tuesday. One research analyst has rated the stock with a sell rating, fourteen have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $85.31.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.